Eureka Award To PPL Therapeutics
PPL Therapeutics has been awarded a Eureka grant of L207,670 ($335,537)by the UK Department of Trade and Industry. The grant will be used to support a L1 million collaborative program with Novo Nordisk of Denmark aimed at improving the production of bioactive proteins and peptides for a variety of therapeutic applications.
PPL's managing director, Ron James, commented: "we are delighted to receive this support from the DTI for our technology development program. In particular, I am pleased that this funding allows us to extend our collaboration with Novo Nordisk, with whom we have been working since 1993. This grant offers the potential to greatly improve the availability of biologically important proteins and peptides for the treatment of a number of medical conditions." The firm is a leader in the transgenic production of recombinant proteins (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze